10-5-2011 18:53:00 @  NewsInferno

Abbotts EVEREST II Study Demonstrates MitraClip Benefits at Two Years Post-Surgery

Abbott Vascular has just announced the latest results from its EVEREST II trial, which has been evaluating the performance of the company's MitraClip Mitral Valve Repair System. The study results, published in The New England Journal of Medicine, show that while the MitraClip was slightly less effective than traditional surgery at treating mitral valve regurgitation, treatment with the device resulted in “increased safety, improved left ventricular dimensions, and clinical improvements in NYHA class and quality of life.” The C

More evidence for MitraClip benefit in frail patients with mitral regurgitation

NEW YORK (Reuters Health) - Two new papers say MitraClip helps improve clinical and echocardiographic outcomes in patients with mitral regurgitation (MR) who don't respond well to maximal drug and device therapy and who aren't candidates for surgery....(read more)

Heart Failure Patients Benefit From MitraClip Therapy

Results of an observational study presented at the European Society of Cardiology (ESC) meeting in Paris demonstrate that the percutaneous catheter-based MitraClip treatment improves symptoms and promotes reverse left ventricular (LV) remodeling in patients with mitral regurgitation (MR), who do not respond to cardiac resynchronization therapy (CRT). The trial, called PERMIT-CARE, is an investigator-led study evaluating the safety and efficacy of MitraClip treatment in 51 patients with clinically significant functional mitral regurgitation (FMR) at seven European centers...